| Identification | Back Directory | [Name]
13C C16 Sphingomyelin (d18:1/16:0) | [CAS]
144236-99-7 | [Synonyms]
13C C16 Sphingomyelin (d18:1/16:0)
C16 Sphingomyelin-13C (d18:1/16:0-13C) | [Molecular Formula]
C39H79N2O6P | [MOL File]
144236-99-7.mol | [Molecular Weight]
704.037 |
| Hazard Information | Back Directory | [Description]
C16 Sphingomyelin-13C (d18:1/16:0-13C) is intended for use as an internal standard for the quantification of C16sphingomyelin by GC- or LC-MS. C16 Sphingomyelin is a naturally occurring sphingolipid. Levels of C16 sphingomyelin are elevated in the prefrontal cortex and cerebellum in a rat model of diabetes induced by streptozotocin (STZ; ), as well as in the liver in mouse models of Niemann-Pick type C1 disease. Plasma levels of C16 sphingomyelin are decreased in patients with prostate cancer. Model membranes containing C16 sphingomyelin, 1-palmitoyl-2-oleoyl-sn-glycero-3-PC (POPC; ), and cholesterol have been used in the study of lipid raft dynamics and membrane organization. [Matreya, LLC. Catalog No. 2200] | [Uses]
N-Palmitoyl-D-sphingomyelin-13C is a deuterated labeled N-Palmitoyl-D-sphingomyelin[1]. N-Palmitoyl-D-sphingomyelin (Sphingomyelin 16:0) (Compound SM-03) can be used for the synthesis of lipid nanoparticles[2]. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] Dandan LING, et al. Lipid compounds and lipid nanoparticle compositions. Patent. WO2023056914. |
|
| Company Name: |
Enzo Biochem Inc
|
| Tel: |
Enzo Biochem Inc. 13797054060 |
| Website: |
www.enzo.com |
|